Kingsview Wealth Management LLC Sells 157,474 Shares of DENTSPLY SIRONA Inc. $XRAY

Kingsview Wealth Management LLC reduced its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 89.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 19,358 shares of the medical instruments supplier’s stock after selling 157,474 shares during the quarter. Kingsview Wealth Management LLC’s holdings in DENTSPLY SIRONA were worth $221,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. First Eagle Investment Management LLC lifted its stake in shares of DENTSPLY SIRONA by 3.2% during the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after acquiring an additional 458,744 shares during the last quarter. Sound Income Strategies LLC lifted its stake in shares of DENTSPLY SIRONA by 32.3% during the 4th quarter. Sound Income Strategies LLC now owns 611,308 shares of the medical instruments supplier’s stock worth $7,464,000 after acquiring an additional 149,384 shares during the last quarter. Invenomic Capital Management LP lifted its stake in shares of DENTSPLY SIRONA by 48.7% during the 3rd quarter. Invenomic Capital Management LP now owns 4,351,199 shares of the medical instruments supplier’s stock worth $55,217,000 after acquiring an additional 1,425,637 shares during the last quarter. Skba Capital Management LLC lifted its stake in shares of DENTSPLY SIRONA by 14.3% during the 3rd quarter. Skba Capital Management LLC now owns 1,140,430 shares of the medical instruments supplier’s stock worth $14,472,000 after acquiring an additional 142,900 shares during the last quarter. Finally, Advisors Asset Management Inc. lifted its stake in shares of DENTSPLY SIRONA by 42.8% during the 3rd quarter. Advisors Asset Management Inc. now owns 348,989 shares of the medical instruments supplier’s stock worth $4,429,000 after acquiring an additional 104,588 shares during the last quarter. 95.70% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on XRAY shares. Mizuho decreased their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Weiss Ratings lowered DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Citigroup started coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They set a “sell” rating and a $10.00 price target for the company. UBS Group decreased their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Zacks Research raised DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Three equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $13.55.

DENTSPLY SIRONA Trading Up 2.5%

Shares of NASDAQ XRAY opened at $9.88 on Friday. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. The business has a fifty day simple moving average of $11.15 and a two-hundred day simple moving average of $11.72. The firm has a market cap of $1.98 billion, a PE ratio of -3.14, a price-to-earnings-growth ratio of 1.15 and a beta of 0.89. DENTSPLY SIRONA Inc. has a twelve month low of $9.40 and a twelve month high of $17.09.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The firm had revenue of $880.00 million for the quarter, compared to the consensus estimate of $841.80 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The company’s revenue for the quarter was up .1% on a year-over-year basis. During the same period last year, the firm earned $0.43 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts expect that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Gregory T. Lucier bought 15,000 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was acquired at an average cost of $12.45 per share, with a total value of $186,750.00. Following the transaction, the director directly owned 65,000 shares in the company, valued at approximately $809,250. This trade represents a 30.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director James D. Forbes purchased 5,000 shares of DENTSPLY SIRONA stock in a transaction dated Monday, March 9th. The stock was bought at an average cost of $12.48 per share, with a total value of $62,400.00. Following the completion of the transaction, the director owned 10,000 shares in the company, valued at approximately $124,800. This represents a 100.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.46% of the company’s stock.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.